A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings. Show 4 more changesShow less
    • Final enrollment: 8 participants — 7% of the 120 planned
    • Primary completion date changed from estimate of Nov 30, 2026 to Sep 11, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    • Eligibility criteria expanded, about 3 words
  2. Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Trial sites expanded: 17 → 20 locations
    • Start date changed from estimate of Jun 2026 to Jun 12, 2026
    v3
  3. Start date: May 2026 to Jun 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
Trial Details
NCT Number NCT07553299
Lead Sponsor Verdiva Bio Dev Limited
Conditions
(from sponsor)		 Obesity, Overweight, Weight Maintenance
Related terms Obesity, Overweight, Weight Loss
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov